Transurethral holmium laser enucleation of prostate shows remarkable efficacy in treating benign prostatic hyperplasia.

OBJECTIVE

To evaluate the effects of transurethral holmium laser enucleation of the prostate (HoLEP) in treating benign prostatic hyperplasia (BPH).

METHODS

This retrospective study included 100 BPH patients who visited Foshan Fosun Chancheng Hospital from January 2022 to June 2023. Patients were divided into two groups: 50 treated with transurethral resection of the prostate (control group) and 50 with transurethral HoLEP (observation group). We compared clinical efficacy, surgical parameters, maximum urinary flow rate (Qmax), post-void residual volume (PRV), prostate-specific antigen (PSA), hemoglobin (Hb), interleukin-6 (IL-6), C-reactive protein (CRP), International Prostate Symptom Score (IPSS), quality of life (QOL), and complication rates.

RESULTS

The observation group showed significantly reduced operative time, blood loss, catheterization duration, and hospitalization compared to the control group (all P<0.05). Postoperatively, Qmax was higher and PRV lower in the observation group (both P<0.05). PSA was lower, and Hb was higher in the observation group than those in the control group (both P<0.05). Both IL-6 and CRP levels increased post-surgery, but were significantly lower in the observation group (both P<0.05). The observation group also had better IPSS and QOL scores and a lower complication rate (16% vs. 56%, all P<0.05).

CONCLUSION

HoLEP is an effective treatment for BPH, offering advantages such as reduced surgical time, lower complication rates, improved urodynamics, and better patient outcomes in terms of symptoms and quality of life.